In this article series, we will introduce the new members of our oncology cluster.
Find out how Glaxo Smith Kline (GSK), the latest global pharmaceutical company to enter into our ecosystem, is contributing to the oncology field.
Glaxo Smith Kline is one of the largest research-based pharmaceutical companies in the world, with over 80 employees located in Norway. The company was founded in 2001, but its history can be traced all the way back to the 1700s. Today, they have an impressive portfolio of vaccines, as well as many promising immunotherapy treatments underway.
We asked a couple of questions to Halvard Grønlien, country medical director of GSK Norway, to find out more about their plans in the oncology area.
Tell us about GSK and how the company is involved in the cancer field.
“GSK is a science-led global healthcare company with more than 100 000 employees in over 150 countries and around 80 people in GSK Norway. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies. Our pharmaceutical and vaccines businesses have a broad portfolio of innovative and established vaccines and medicines with commercial leadership in respiratory and HIV. Our vaccines business has a portfolio of more than 30 vaccines, helping to protect people against 21 diseases. We are the biggest supplier of vaccines to the Norwegian immunization program. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies, and our strategy is to bring differentiated, high-quality and needed healthcare products to as many people as possible.
“Within oncology, we are committed to maximizing patient survival through the development of transformational medicines. Since 2018, we have more than doubled the number of oncology assets in clinical development through our own science, the acquisition of TESARO and other alliances. We aim to deliver a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. Our innovative portfolio focuses on four cutting edge areas of science that we believe offer the greatest opportunities to provide meaningful solutions for patients:
- Immuno-oncology: using the human immune system to treat cancer
- Cell therapy: engineering human T-cells to target cancer
- Cancer epigenetics: modulating the gene-regulatory system of the epigenome to exert anti-cancer effects
- Synthetic lethality: targeting two mechanisms at the same time which together, but not alone, have substantial effects against cancer”
Why did GSK join Oslo Cancer Cluster?
“GSK has an increasing pipeline of new oncology assets and in the process of establishing a network within oncology. Oslo Cancer Cluster is an important part of the oncology landscape in Norway and indeed an important partner for GSK. We are looking forward to partnering with Oslo Cancer Cluster when arranging scientific meetings and dialogues, bringing investigators together for fruitful clinical research collaborations, and bridging GSK global discovery team with biotech/startup community in Norway looking for new R&D investments.”
- Find out more on GSK’s official website